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Abstract
Objective: To assess the prevalence of three liver diseases [hepatitis C virus (HCV), nonalcoholic fatty liver disease and alcohol-induced
cirrhosis] in patients (veterans) with/without schizophrenia/schizoaffective disorder and bipolar disorder.
Methods: A retrospective electronic chart review of Veterans Integrated Services Network 20 facilities from January 1, 2001 to December
21, 2006 selected patients to one of two groups: schizophrenia/schizoaffective disorder or bipolar disorder. Patients in both groups were
compared with veterans in an equal-sized random sample from the same data set of veterans without psychiatric diagnoses. Logistic
regression models evaluated risk for overall liver diseases as well as HCV, nonalcoholic fatty liver disease and alcoholic-induced cirrhosis.
Results: Patients with schizophrenia (n=6521) had a higher prevalence of liver disease [22.4% versus 3.2%; odds ratio (OR)=8.73]; HCV
(16.5% versus 1.9%; OR=10.21); and alcohol-related cirrhosis (1.6% versus 0.4%; OR=4.09) than matched controls. Patients with bipolar
disorder (n=5319) had a higher prevalence of liver disease (21.5% versus 3.5%; OR=7.58); HCV (15.5% versus 2.1%; OR=8.60); and
alcohol-related cirrhosis (1.6% versus 0.4%; OR=3.82) than matched controls. Risk factors for liver disease in patients with schizophrenia
(versus matched controls) included diabetes (OR=1.29), hypertension (OR=1.27), HIV (OR=3.54), substance use disorder (SUD) (OR=2.28),
alcohol use disorder (OR=3.05) and schizophrenia (OR=2.74). Risk factors for development of liver disease for patients with bipolar
disorder: diabetes (OR=1.40), HIV (OR=3.66), SUD (OR=2.68), alcohol use disorder (OR=3.22) and bipolar disorder (OR=2.27).
Conclusions: This study in veterans shows that the presence of mental illness and its comorbidities represents a significant risk factor for the
diagnosis of liver disease, including HCV and alcohol-related cirrhosis.
Published by Elsevier Inc.
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1. Introduction
Epidemiologic studies show that, among Axis I diagnoses,
bipolar disorder and schizophrenia have been associated with
the highest risk for comorbid substance use disorders (SUDs)
[1–5]. Selected studies found that among individuals with
serious mental illness (SMI)—primarily schizophrenia or
schizoaffective disorder diagnoses—45.9% had SUDs,
20.1% had injected drugs and 14.5% had shared needles
[4,5]. Other studies suggest that over 50% of patients with
bipolar disorder have a past or present SUD. This SUD
comorbidity is associated with a higher risk of suicide
attempts, hospitalizations, mood episodes and days ill [1,2,6].
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The presence of SUD also increases the risk of liver disease,
particularly chronic hepatitis C virus (HCV) infection and
alcohol-related liver diseases. HCV infection is the most
common blood-borne viral infection in the US; approximately
1.8% of the general population is chronically infected [7].
Despite the lower numbers of HCV infections among active-
duty personnel and reservists, the prevalence of HCV infection
in veterans using Veterans Affairs (VA) facilities has
repeatedly been shown to be higher than the general
population. Dominitz et al. [8] found that an estimated 5.4%
of veterans who access medical care through the VA are
infected with HCV, three times the prevalence in the general
population. Injection drug use continues to represent the
primary mode of transmission for HCV. It is estimated that
approximately 60% of the 4 million existing cases of HCV
infection and two thirds of the 35,000 new cases of HCV
infection in theUS each year result directly from injection drug
use behavior [9,10]. Various cross-sectional seroprevalence
studies suggest that 60% to 90% of injection drug users are
HCV-antibody positive [11]. However, relative to the general
population, the prevalence of HCV infection is also high
among non-injection drug users. One study of 700 non-
injection drug users (heroin, cocaine or crack) showed that the
prevalence of HCV infection ranged from 5% to 29%,
depending on age, gender, study location and drugs used [12].
An initial study of veterans accessing Veterans Integrated
Services Network (VISN) 20 facilities in Alaska, Idaho,
Oregon and Washington examined the prevalence of HCV
infection in veterans with schizophrenia and schizoaffective
disorder. Over 293,000 veterans who used VISN 20 facilities
between 1998 and 2003 were divided into four groups: (1)
patients with schizophrenia or schizoaffective disorder but
no SUD (4,192 veterans); (2) patients with an SUD but no
schizophrenia or schizoaffective disorder (39,922 veterans);
(3) patients with a history of both schizophrenia or
schizoaffective disorder and SUD (4,644 veterans); and (4)
patients with no history of schizophrenia or schizoaffective
disorder or SUD (244,597 veterans). Approximately 47.5%
of the veterans with schizophrenia or schizoaffective
disorder but no SUD were tested for HCV; of these, 9.9%
had confirmed HCV infection. Among the veterans with
only an SUD, 63.0% were tested for HCV and 27.0% of
these had confirmed HCV infection. Among the veterans
with schizophrenia or schizoaffective disorder and an SUD,
72.3% were tested for HCV, of whom 31.1% had confirmed
HCV infection. This compared with a testing rate of 30.1%
and an infection rate of HCV of 5.3% in veterans with neither
SUD nor schizophrenia or schizoaffective disorder [13].
In a second study, using the same VISN 20 electronic
database but including veterans seen between 1998 and 2004,
we examined the prevalence of HCV infection in veterans who
had bipolar disorder with comorbid SUD (4700) and without
comorbid SUD (5026). Again, findings showed that veterans
with bipolar disorder were at higher risk for HCV infection
than those without bipolar disorder. Among those tested who
had bipolar disorder with SUD (81.7%), 29.6% had confirmed
HCV infection; among those tested who had bipolar disorder
but no comorbid SUD (59.8%), 7.1% had confirmed HCV
infection [14]. These two studies suggest that patients with
bipolar disorder or schizophrenia are at high risk for HCV
infection, particularly if they have comorbid SUDs.
The current study expanded these initial findings by
examining the prevalence of three liver diseases [HCV
infection, nonalcoholic fatty liver disease (NAFLD) and
alcohol-related cirrhosis] in veterans with bipolar disorder or
schizophrenia or schizoaffective disorder, while controlling
for other possible factors associated with SMI such as
demographic variables, physical disease, and SUD. Adjusted
odds ratios (ORs) are presented in a series of logistic
regression models. No adjustment was made for multiplicity.
2. Methods
2.1. Study design
A retrospective analysis of data included in the VISN 20
Consumer Health Information and Performance Set Data
Warehouse examined data on all patients seen between 2001
and 2006 in VISN 20 facilities and clinics. This study was
approved by the Portland VA Medical Center Institutional
Review Board, and all principles outlined in the Declaration
of Helsinki were followed. Patient data were examined for
presence of at least two ambulatory encounters or one
inpatient hospital encounter with the diagnosis of schizo-
phrenia or bipolar disorder, based on International Classi-
fication of Diseases, 9th Revision, Clinical Modification
(ICD-9-CM) codes, during the period from January 1, 2001,
to October 31, 2006. The study sample was divided into two
groups: (1) those with schizophrenia or schizoaffective
disorder and (2) those with bipolar disorder. For each veteran
with schizophrenia or bipolar disorder, an individual without
a psychiatric diagnosis was randomly selected from the
database creating four independent groups: (1) schizophrenia
patients, (2) no schizophrenia controls, (3) bipolar patients
and (4) non-bipolar controls. These four groups were then
analyzed for psychiatric, substance abuse and health-related
predictors related to the development of liver diseases.
2.2. Data analysis
The prevalence of liver disease-related ICD-9-CM codes
was compared among groups after taking into account the
differences in age gender, and whether the patient died
during the observation period. In order to investigate the
effects of risk factors on liver disease, a forward-entry
logistic regression model was calculated with the dependent
variables of overall liver disease and separately for three
specific liver diseases (chronic HCV infection, alcohol-
related cirrhosis and NAFLD). In Step 1, age, gender, and
death were entered as covariates in one block. In Step 2,
diabetes, obesity, hypertriglyceridemia, hypertension, cur-
rent and past drug use diagnosis, alcohol use and current
human immunodeficiency virus (HIV) infection were
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entered. In the last step, bipolar disorder or schizophrenia
was entered to determine the adjusted odds ratios of the
presence of liver disease in patients with schizophrenia or
bipolar disorder. Structured Query Language (SQL v. 2008)
was used for all data management and SPSS (v.17) was used
to analyze these data. Interactions among the predictors were
not specified in this model because all of the predictors were
dichotomous variables. Thus, there was not sufficient
variance to include both main effects and interactions
based on two non-normally distributed binary variables.
3. Results
3.1. Study sample
We identified 6521 patients with schizophrenia and 5319
patients with bipolar disorder. The majority of patients were
male (schizophrenia sample, 93.8%; bipolar disorder sample,
90.2%). Approximately 12% died during the observation
period (schizophrenia, 11.9%; bipolar disorder, 12.2%). The
average age of patients in the groups with SMI was lower
(schizophrenia, 57.2 years; bipolar disorder, 54.3 years) than
in the control groups (schizophrenia control group, 62.4 years;
bipolar disorder control group, 62.6 years). This difference
may be due in part to the fact that patients with SMI are likely
to seek treatment earlier because of mental health concerns.
Rather thanmatch the controls for age, which would distort the
natural characteristics of this sample, we chose to statistically
control for the effects of age by entering it first in the regression
equations. Veterans with an alcohol use disorder composed
50.2% of the schizophrenic sample and 5.4% of controls;
51.1% of the bipolar sample and 5.2% of their controls. The
percentage of veterans with a drug use disorder diagnosis was
65.0% for schizophrenic veterans and 11.6% of their controls;
60.3% for bipolar veterans and 11.7% of their controls.
3.2. Veterans with schizophrenia
Table 1 presents percentages and unadjusted odds ratios
of the risk of developing three specific liver diseases and the
rates of overall liver diseases in veterans with schizophrenia
or schizoaffective disorder. The ORs for the 6521 veterans
with schizophrenia show a higher prevalence of overall liver
disease (22.4%) than the set of veterans without SMI (3.2%).
The OR was 8.73, indicating the schizophrenia diagnosis
increased the likelihood of having a liver disease eightfold.
The prevalence of HCV infection was also higher for
veterans with schizophrenia, alcohol-related cirrhosis, and
NAFLD. All ORs were significant at the Pb.001 level.
3.3. Overall liver disease
A logistic regression model (Table 2) demonstrates that
veterans with liver diseases were more likely to be male and
younger (probably because the SMI group was younger) and
were more likely to have died during the observation period.
The significant risk factors for liver disease were diabetes
Table 1
Percentages and odd ratios of the risk for liver disease in veterans with and
without schizophrenia and bipolar disorder
Disease With SZ
(n=6521)
Without SZ
(n=6521)
OR Lower
95% CI
Upper
95% CI
Overall liver
disease
22.4 3.2 8.7 7.5 10.1
HCV
infection
16.5 1.9 10.2 8.4 12.3
Alcoholic
cirrhosis
1.6 0.4 4.1 2.6 6.3
NAFLD 1.5 0.2 7.5 4.2 13.3
With BP
(n=5319)
Without BP
(n=5319)
OR Lower
95% CI
Upper
95% CI
Overall liver
disease
21.5 3.5 7.6 6.4 8.8
HCV
infection
15.5 2.1 8.6 7.0 10.5
Alcoholic
cirrhosis
1.6 0.4 3.8 2.3 6.1
NAFLD 1.1 0.3 3.3 1.9 5.6
BP, bipolar disease; SZ, schizophrenia.
All ORs are significant at Pb.05.
Table 2
Logistic regression models for patients with schizophrenia compared with controls
Variable Overall liver disease
(N=13,042)
HCV infection (N=13,042) Alcohol-related cirrhosis
(N=13,042)
NAFLD (N=13,042)
Adj OR S.E. P value Adj OR S.E. P value Adj OR S.E. P value Adj OR S.E. P value
Gender 0.616 0.148 .001 0.450 0.195 b.001 0.230 1.012 .015 0.960 0.429 .924
Age 0.981 0.003 b.001 0.979 0.003 b.001 0.982 0.009 .040 1.000 0.009 .664
Died 1.625 0.085 b.001 1.163 0.100 .130 5.334 0.197 b.001 1.105 0.277 .719
Diabetes 1.289 0.076 .001 1.377 0.089 b.001 2.299 0.217 b.001 1.414 0.229 .130
Obesity 1.002 0.072 .975 0.710 0.085 b.001 0.561 0.250 .021 1.453 0.222 .092
Hypertriglyceridemia 0.986 0.153 .926 0.488 0.212 .001 0.313 0.733 .113 2.076 0.351 .038
Hypertension 1.272 0.065 b.001 1.014 0.074 .085 0.988 0.205 .953 1.359 0.225 .172
HIV 3.543 0.282 b.001 3.775 0.284 b.001 0.988 0.635 .319 2.313 0.733 .252
SUD 2.279 0.087 b.001 2.993 0.107 b.001 1.198 0.333 .588 1.181 0.271 .538
Alcohol use disorder 3.049 0.076 b.001 2.915 0.088 b.001 38.450 0.435 b.001 1.345 0.252 .239
SZ 2.736 0.089 b.001 3.118 0.111 .000 0.525 0.254 .011 4.932 0.330 b.001
Adj, adjusted.
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(OR=1.29), hypertension (OR=1.27), HIV (OR=3.54), SUD
(OR=2.28) and alcohol use disorder (OR=3.05). The adjusted
odds ratio for the presence of schizophrenia when controlling
for the other covariates showed that the risk of having overall
liver disease increased by almost threefold for those with
schizophrenia (OR=2.74). All ORs were significant atPb.005.
3.4. Hepatitis C virus infection
Another model also presented in Table 2 examined the
same set of risk factors for HCV infection in patients with
and without schizophrenia. Results for HCV infection were
similar to those for overall liver disease, as veterans with
HCV were more likely to be male and younger. Additional
significant risk factors were diabetes (OR=1.37), HIV
(OR=3.77), SUD (OR=2.90) and alcohol use disorder
(OR=2.92). Obesity (OR=0.71) and hypertriglyceridemia
(OR=0.49) were lower for those with HCV were less likely
to have a diagnosis of obesity or hypertriglyceridemia. The
presence of schizophrenia elevated the risk of having HCV
infection threefold after controlling for the other health
effects (OR=3.11). All ORs were significant at Pb.001.
3.5. Alcohol-related cirrhosis
The logistic regression model in Table 2 indicated that
people with alcohol-related cirrhosis were more likely to be
male and to have died during the observation period. Other
significant risk factors were diabetes (OR=2.29) and alcohol
use disorder (OR=38.45). Protective factors included obesity
(OR=0.56) and the presence of schizophrenia (OR=0.53).
All ORs were significant at Pb.05.
3.6. Nonalcoholic fatty liver disease
The model in Table 2 examined risk factors for NAFLD in
patients with and without schizophrenia. The significant risk
factors were hypertriglyceridemia (OR=2.07) and presence of
schizophrenia (OR=4.93). All ORs were significant at Pb.05.
3.7. Veterans with bipolar disorder
Veterans with bipolar disorder (n=5319) also had a higher
prevalence of overall liver disease (21.5%) than a matched
set of veterans without bipolar disorder (3.5%; OR=7.58)
(Table 1). The prevalence of HCV infection (15.5% versus
2.1%; OR=8.60) and alcohol-related cirrhosis (1.6% versus
0.4%; OR=3.82) were higher for veterans with bipolar
disorder as well. All ORs were significant at Pb.05 and are
presented in Table 1.
3.8. Any liver disease
A model for patients with bipolar disorder with the
dependent variable of any liver disease indicated that patients
were more likely to be male, to be younger and to have died
during the observation period. The risk factors for the
presence of liver disease were diabetes (OR=1.40), HIV
infection (OR=3.66), SUD (OR=2.68) and alcohol use
disorder (OR=3.22). Bipolar disorder elevated the risk of
liver disease as well (OR=2.27). Table 3 presents the logistic
regression models for patients with bipolar disorder
compared with controls. All ORs were significant at Pb.005.
3.9. Hepatitis C virus infection
Veterans with HCV infection were more likely to be male,
to be younger, and to have died during the observation
period. Table 3 shows that the risk factors for contracting
HCV infection were hypertriglyceridemia (OR=1.59), HIV
infection (OR=2.88), SUD (OR=3.46) and alcohol use
disorder (OR=3.26). Similar to the overall liver disease
results, bipolar disorder elevated risk of HCV infection
(OR=2.31). All ORs were significant at Pb.005.
3.10. Alcohol-related cirrhosis
A logistic regression examined a set of risk factors for
alcohol-related cirrhosis for patients with and without
bipolar disorder. Patients with alcohol-related cirrhosis
Table 3
Logistic regression models for patients with bipolar disorder compared with controls
Variable Overall liver disease
(N=10,638)
HCV infection (N=10,638) Alcohol-related cirrhosis
(N=10,638)
NAFLD (N=10,638)
Adj OR S.E. P value Adj OR S.E. P value Adj OR S.E. P value Adj OR S.E. P value
Gender 0.698 0.122 .003 0.546 0.153 b.001 0.445 0.598 .176 1.716 0.336 .107
Age 0.988 0.003 b.001 0.989 0.004 .001 0.998 0.010 .833 0.994 0.010 .574
Died 1.954 0.106 b.001 1.594 0.121 b.001 5.081 0.227 .000 1.600 0.347 .176
Diabetes 1.404 0.088 b.001 1.185 0.104 .102 2.393 0.235 .000 2.498 0.269 .001
Obesity 1.108 0.081 .205 0.960 0.094 .667 0.889 0.261 .651 0.881 0.283 .654
Hypertriglyceridemia 0.797 0.205 .268 0.494 0.283 .013 0.645 0.737 .553 1.944 0.481 .167
Hypertension 1.207 0.073 .010 1.047 0.083 .580 0.982 0.224 .935 1.467 0.271 .157
HIV 3.658 0.274 b.001 2.888 0.288 b.001 2.795 0.627 .101 NAa NAa NAa
SUD 2.682 0.099 b.001 3.463 0.126 b.001 0.981 0.338 .954 1.145 0.317 .670
Alcohol use disorder 3.216 0.092 b.001 3.263 0.111 b.001 36.687 0.454 .000 0.985 0.322 .964
BP 2.269 0.098 b.001 2.312 0.122 b.001 0.616 0.290 .095 2.565 0.316 .003
N.A., not applicable.
a HIV was removed from this model because there were no cases of NAFLD in participants with HIV.
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were more likely to have died during the observation period.
Results indicated that for patients with alcohol-related
cirrhosis, significant risk factors were diabetes (OR=2.39)
and alcohol use disorder (OR=36.68). Bipolar disorder was
not significant (OR=0.616; P=.095).
3.11. Nonalcoholic fatty liver disease
A model examined risk factors for NAFLD for patients
with and without bipolar disorder, demonstrating that the risk
factors were diabetes (OR=2.50; Pb.001) and the presence
of bipolar disorder (OR=2.57; Pb.003). HIV infection was
removed from this model because there were no cases of
NAFLD in patients with HIV infection.
4. Discussion
This study demonstrated that the presence of SMI was a
significant risk factor for the diagnosis of liver disease,
including HCV infection and NAFLD. Even when other
conditions were controlled, the prevalence of liver disease
was approximately 2–2.5 times higher in veterans with SMI.
However, this effect was associational because the study
design did not assess causation. These results also indicated
that veterans with liver disease were significantly more likely
to have comorbid conditions. Earlier reports of the
relationship between SMI and liver disease [13] did not
account for other competing causes such as health conditions
and alcohol and drug use. In this manuscript, we are able to
conclude that this relationship is maintained even with
significant covariates.
4.1. Hepatitis C virus infection
People with HCV were more likely to be younger,
indicating they have earlier contact with medical providers
because of early identification and mandatory testing and
notification efforts. They were also more likely to be male as
this was a study of veterans. Veterans with HCV and bipolar
disorder were more likely to die during the observation period
but this was not observed for veterans with schizophrenia.
HIV infection and drug use disorders (SUD) were uniquely
significant covariates for both bipolar and schizophrenic
veterans with HCV likely due to the common set of risk
factors (i.e., needle sharing) for transmission of both blood-
borne diseases. Alcohol use disorders were also higher for
both schizophrenic and bipolar veterans with HCV likely due
to the comorbidity of alcohol and drug use.
A paradoxical finding for the schizophrenic sample
showed that obesity and hypertriglyceridemia were less
likely among HCV patients. The simple unadjusted odds
ratio between obesity and HCV (OR: 1.37; 95% CI 1.19–
1.59) was greater than 1.00, indicating that when observed
without covariates, obesity was more likely to be present in
veterans with HCV. The unadjusted odds ratio between
hypertriglyceridemia and HCV was OR: 1.15 (95% CI .69–
1.51). Thus, a previously not significant relationship became
a “protective factor.” These two protective effects in the
model are likely due to statistical suppression and not
evidence for a true protective factor.
4.2. Alcohol-related cirrhosis
The simple ORs among SMIs and alcohol-related
cirrhosis were significant risk factors (see Table 1).
However, when the covariates were added into the model
the presence of SMI did not predict an increase in alcohol-
related cirrhosis except for a weak effect Pb.011 in the
schizophrenia sample. This effect was likely due to the large
effect that alcohol has on the development of cirrhosis.
Diabetes and obesity were strongly predictive of the
presence of cirrhosis as well indicating that lifestyle choices
contribute to the development of cirrhosis to a large degree.
Thus, the effect of SMI on cirrhosis was overwhelmed by
inclusion of lifestyle factors such as diet, exercise and
alcohol use. Statistical suppression changed the valence of
the odds ratio for presence of schizophrenia from a risk factor
to a protective factor.
4.3. Nonalcoholic fatty liver disease
The patients with NAFLD had fewer covariates that were
significant predictors of their disease. However, both bipolar
and schizophrenia were both positive predictors of NAFLD.
Diabetes was the only predictor for the bipolar sample that
was significant. The exact cause of NAFLD is still unknown;
however, both obesity and diabetes play a strong role in the
development of this disease. The exact reasons and
mechanisms by which the disease progresses from one
stage to the next are not known.
5. Conclusions
Given the high incidence of SUD comorbidities, veterans
with bipolar disorder or schizophrenia are at increased risk for
HCV infection and alcohol-related cirrhosis. Hepatitis A and
B virus infections were not examined in this study because of
very few reported cases in the database. Although the
presence of acute and chronic hepatitis A and hepatitis B
virus infectionmay also be higher in patients with SMI, future
studies will need to determine whether this is a reportable
trend. Alcohol use accelerates the liver damage caused by
HCV. Efforts aimed at encouraging lifestyle choices that
reduce alcohol use are important in order to minimize their
impact on liver health in veterans with liver disease. Such
interventions are vitally important to people with SMI and
liver disease. An important strategy to consider in patients
with liver disease is screening for alcohol problems using
short instruments such as the three-item Alcohol Use
Disorders Identification Test-Consumption module [15]
with positive results followed by brief motivational enhance-
ment therapy interventions. Patients with SMI and liver
disease should be given priority for such interventions, as
well as referrals to substance abuse treatment services, to
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reduce the progression toward cirrhosis. Another conside-
ration for veterans with bipolar disorder and schizophrenia is
choice of medication and the effect of medications on liver
function. Research shows that liver disease testing and
education can alter behavior and improve treatment for
substance abuse. Rifai et al. [16] initiated routine or universal
HCV screening in a substance abuse treatment community
clinic where 23% of veterans were HCV positive. Veterans
who were HCV positive were more likely to remain abstinent
after treatment and were more likely to stay in treatment than
those who were HCV negative.
Factors such as homelessness, use of atypical antipsy-
chotic medication or inpatient hospital admissions were not
able to be measured in this study. Limitations such as these
are common in large retrospective studies. Additional
research would be helpful in explicating the effects of
some of these additional factors. More complex modeling
with interactions is also difficult with data that are binary,
and thus, some variation was not able to be modeled.
Willenbring [17] and others [18–23] suggest that integrated
health care models are an important aspect of the treatment of
this population. HCV-positive patients are more likely to have
psychiatric, cognitive and SUD comorbidities; coinfection
withHIV; aswell as additional social problems, such as lack of
housing, transportation, and income. These problems present
serious barriers to treatment and management of care.
Treatment that is fragmented in separate locations or through
inadequate communication within a system only serves to
ensure poor adherence, treatment dropouts and poorer out-
comes. The integration of substance abuse treatment services,
mental health services, social services and hepatology and
internal medicine specialists can greatly improve communi-
cation and coordinate care. Fully integrated multidisciplinary
teams have been used to improve disease management for
many other disease models and can be done for this population
aswell. Careful monitoring of the approach and quality control
procedures will maximize chances that a model such as this
would work to provide the best services for this medically and
psychologically complex population.
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